• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aligos Therapeutics downgraded by JP Morgan with a new price target

    1/7/22 5:06:08 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALGS alert in real time by email
    JP Morgan downgraded Aligos Therapeutics from Overweight to Neutral and set a new price target of $12.00 from $30.00 previously
    Get the next $ALGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALGS

    DatePrice TargetRatingAnalyst
    8/19/2024$75.00Buy
    H.C. Wainwright
    1/6/2023$2.00 → $3.00Neutral → Overweight
    Piper Sandler
    1/6/2023$2.50 → $3.00Hold → Buy
    Jefferies
    3/23/2022$15.00 → $4.00Overweight → Neutral
    Piper Sandler
    3/11/2022$47.00 → $15.00Overweight
    Piper Sandler
    3/11/2022$10.00 → $11.00Outperform
    SVB Leerink
    2/16/2022$15.00 → $10.00Outperform
    SVB Leerink
    1/7/2022$30.00 → $12.00Overweight → Neutral
    JP Morgan
    More analyst ratings